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Pharmacological Treatment in
Asthma and COPD
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ABSTRACT
Many lines of previous studies have reported that differences and similarities between bronchial asthma (BA)
and chronic obstructive pulmonary disease (COPD). The pathological and physiological abnormalities of these
diseases have been also discussed. BA and COPD have some similarities such as airflow obstruction, pulmo-
nary inflammation, and airway hyperresponsiveness (AHR). However, both two diseases are regarded different
diseases since their mechanisms of development are quite different. Therefore, both two diseases require dif-
ferent assessment, monitoring, and pharmacological treatments. In this paper, we describe the pharmacologi-
cal treatment of asthma in adults and COPD based on recently updated guideline by the Global Initiative for
Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD), respectively.
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PHARMACOLOGICAL TREATMENT FOR
STABLE ASTHMA IN ADULTS (GREATER
THAN OR EQUAL TO 12 YEARS OF AGE)
Since BA has airflow obstruction due to airway in-
flammation and hyperresponsiveness, anti-
inflammatory therapy and bronchodilating therapy
should be considered.1 Airway inflammation in BA re-
sponds to steroid very well, thus inhaled glucocorti-
costeroids are the first choice for the treatment for
BA. Assessment should address daytime symptoms,
nighttime symptoms, use of short acting inhaled beta
agonists to relieve symptoms, and difficulty in per-
forming normal activities and exercise at each visit. A
simplified scheme for recognizing controlled, partly
controlled and uncontrolled asthma has been pub-
lished by GINA1 (Table 1). The management ap-
proach to pharmacological treatment is based on in-
creasing medications until asthma is controlled, and
decreasing medications when possible to minimize
side effects. The patient’s management should be ad-
justed, if needed, at every visit1 (Fig. 1). For example,
if asthma is not controlled on the current regimen,
treatment should be stepped up until control is
achieved. If control has been maintained for at least
three months, treatment can be stepped down. The
scheme of the pharmacological treatment for BA is
shown in Figure 2.1 Commonly used drugs including
bronchodilators and glucocorticosteroids are shown
in Table 2.
Intermittent (Step 1): Patients with mild intermit-
tent asthma are best treated with a short-acting in-
haled beta-2-selective agonist such as salbutamol and
procaterol, taken as needed for relief of symptoms.
Mild persistent (Step 2): The distinction between
intermittent and mild persistent asthma is important,
because the GINA guideline calls for initiation of
long-term controller medication in patients with mild
persistent asthma.1 The preferred long-term control-
ler for mild persistent asthma is low dose inhaled glu-
cocorticosteroids (Fig. 2). Regular use of inhaled glu-
cocorticosteroids reduces the frequency of symptoms
and the need for SABAs for symptom relief. In addi-
tion, it improves the overall quality of life, and de-
creases the risk of serious exacerbations.2 Alternative
pharmacological treatment of mild persistent asthma
includes leukotriene receptor antagonists. Patients
receiving long-term controller therapy also should
continue to use their short-acting beta agonist as
needed for relief of symptoms.
Moderate persistent (Step 3): The pharmacological
treatments for moderate persistent asthma are either
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Table 1 Levels of asthma control: a scheme for recognizing controled, partly controled and uncontroled asthma
UncontroledPartly controled(Any measure present in any week)
Controled
(Al of the folowing)Characteristic
Three or more features of partly 
controled asthma present in any 
week
More than twice/weekNone (twice
or less/week)
Daytime symptoms
AnyNoneLimitations of activities
AnyNoneNocturnal
symptoms/awakening
More than twice/weekNone (twice or
less/week)
Need for reliever/
rescue treatment
<80% predicted or
personal best (if known)
NormalLung function (PEF
or FEV1)†
One in any week§One or more/year‡NoneExacerbation
†Lung function is not a reliable test for children 5 years and younger.
‡Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate.
§By definition, an exacerbation in any week.
Quoted from reference 1.
Fig. 1 The management approach to pharmacological treatment for asthma. Quoted from reference 1.
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Treatment Action
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low-doses of an inhaled glucocorticosteroids plus a
long-acting inhaled beta agonist (LABAs), medium-
or high-doses of an inhaled glucocorticosteroids, low
doses of an inhaled glucocorticosteroids plus leukot-
riene receptor antagonists, or low doses of an inhaled
glucocorticosteroids plus sustained release theophyl-
line. The combination of low-doses of an inhaled glu-
cocorticosteroids plus LABAs may be more effective
in controlling asthmatic symptoms than increasing
the dose of inhaled glucocorticosteroids alone.
Severe persistent (Step 4): The preferred treat-
ments for severe persistent asthma are medium- or
high-doses of an inhaled glucocorticosteroids in com-
bination with LABA. When patients are inadequately
controlled on high-dose inhaled glucocorticosteroids
plus LABAs, add a leukotriene modifier (leukotriene
receptor antagonist or lipoxygenase inhibitor) andor
sustained release theophylline.
Severe persistent (Step 5): The preferred treat-
ments for severe persistent asthma are high doses of
an inhaled glucocorticosteroids plus LABAs. In addi-
tion, for patients who are inadequately controlled on
high-dose inhaled glucocorticosteroids and LABAs,
add lowest dose of oral glucocorticosteroids. Re-
cently, anti-IgE humanized monoclonal antibody
omalizumab (XolairⓇ) is available in Japan. The anti-
IgE therapy omalizumab may be considered in com-
bination with other treatments for very severe asthma
patients who are resistant against treatment with high
doses of an inhaled glucocorticosteroids plus LABAs.
PHARMACOLOGICAL TREATMENT FOR
ACUTE EXACERBATIONS OF ASTHMA IN
ADULTS
Patients with mild asthma attack require inhaled
rapid-acting beta2-agonists in adequate doses using a
metered dose inhaler (MDI). Begin with 2 to 4 puffs
every 20 min for first hour. However, patients with
acute exacerbations of asthma often require systemic
glucocorticosteroids. The best strategy for manage-
ment of acute exacerbations of asthma is early recog-
nition and intervention, before asthma attacks be-
come severe and potentially life threatening. Previous
studies have frequently revealed that failures on the
part of both patients and clinicians to recognize the
severity of the disease and to intensify treatment ap-
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Fig. 2 The scheme of the pharmacological treatment for asthma.
†Inhaled glucocorticosteroids. ‡Receptor antagonist or synthesis inhibitors. Quoted from reference 1.
Treatment Steps
Asthma education
Environmental control
As needed rapid-
acting β2-agonist
Reduce Increase
Step 1 Step 5Step 4Step 3Step 2
Controller
options
Select one
Low-dose inhaled
ICS̐
Leukotriene
modifier‡
Select one
Low-dose ICS plus
leukotriene modifier
Low-dose ICS plus
sustained release
theophylline
Medium-or
high-dose ICS
Add one or more
Leukotriene
modifier
Sustained release
theophylline
Add one or both
Oral glucocorticosteroid
(lowest dose)
Anti-lgE
treatment
As needed rapid-acting β2-agonist
Low-dose ICS plus
long-acting β2-agonist
Medium-or high-dose
ICS plus long-acting
β2-agonist
propriately. Thus GINA strongly recommends “Do
not underestimate the severity of an attack”.1
Assess the severity of the attack as follows.1 Pa-
tients should immediately seek medical care if:
1. The attack is severe: for example, the patients is
breathless at rest, is hunched forward, talks in words
rather than sentences, is agitated, drowsy, or con-
fused, has bradycardia, or has a respiratory rate
greater than 30 per minute. Wheeze is loud or absent.
Pulse is greater than 120min. PEF is less than 60% of
predicted or personal best, even after initial treat-
ment. The patient is exhausted.
2. The response to initial bronchodilator treatment
is not prompt and sustained for at least 3 hours.
3. There is no improvement within 2 to 6 hours af-
ter oral glucocorticosteroids is started.
4. There is further deterioration.
Asthma attacks require following prompt treatment.
1. Use inhaled short-acting beta agonists early and
frequently. The mainstay of bronchodilator treatment
is inhalation of short-acting beta-2-selective adrener-
gic agonists, such as salbutamol and procaterol. The
standard regimen for initial care has become salbuta-
mol (or an equivalent) 1.5 to 2.5 mg by continuous
flow nebulization every 20 minutes for the first hour,
then 1.5 to 5 mg every 1 to 4 hours as needed. An-
other protocol calls for administration by MDI with a
spacer. Begin with 2 to 4 puffs every 20 minutes for
the first hour; then mild exacerbation will require 2 to
4 puffs every 3 to 4 hours, and moderate exacerbation
6 to 10 puffs every 1 to 2 hours.
2. Start systemic glucocorticosteroids if there is not
an immediate and marked response to the inhaled
short-acting beta agonists. The onset of action of sys-
temic glucocorticosteroids is not clinically apparent
until as long as 6 hours after administration. Early ad-
ministration is though to help to minimize the delay
in improvement anticipated with systemic glucocorti-
costeroids. Oral glucocorticosteroids; the equivalent
of a prednisone dose of 40 to 80 mg (0.5 to 1 mg per
kg) per day in a single or divided dose is typical. In-
travenous glucocorticosteroids should be given to pa-
tients who present with impending or actual respira-
tory arrest, or patients who respond poorly to oral
glucocorticosteroids. A massive initial dose (e.g.
methylprednisolone 500 mg) is no more effective
than a large initial dose (125 mg)3; significantly
smaller doses (e.g. 60 to 80 mg) may be sufficient.
3. Oxygen is given if the patient is hypoxemic
(achieve O2 saturation of 95%).
4. Make frequent (every 1 to 2 hours) objective as-
sessments of the response to therapy until definite,
sustained improvement is documented.
5. Admit patients who do not respond well after 4 to
6 hours to a setting of high surveillance and care.
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Duration of action
(hours)
Vials for injection
(mg)
Oral, flow nebulization,
trans-dermalInhaler (μg)Drug
β2-agonists
Short-acting β2-agonists
(SABAs)
4-6*Flow nebulization1.5-2.5 mg
100, 200
(MDI & DPI)Salbutamol
8-1025, 50 μg (Pil)10-20 (MDI)Procaterol
Long -acting β2-agonists
(LABAs)
12+25-50(MDI & DPI)Salmeterol
12-24*Trans-dermalTulobuterol
0.5, 1, 2 mg
Anticholinergics
Short-acting
6-820, 40 (MDI)Ipratropium bromide
7-9100 (MDI)Oxitropium bromide
Long-acting
24+18 (DPI)Tiotropium
Methylxanthines
Variable, up to 24250 mg100 mg (Pil)Aminophyline
Variable, up to 2450-400 mg (Pil)Theophyline
Inhaled glucocorticosteroids
50-100 (MDI)Beclomethasone
100, 200 (DPI)Budesonide
50-200
(MDI & DPI)Fluticasone
Combination of long-
acting β2-agonists plus
glucocorticosteroids
50/100, 250, 500
(DPI)Salmeterol/Fluticasone
Leukotriene receptor
antagonist
1.15112.5 mg (Pil)Pranlukast
7.520, 40 mg (Pil)Zafirlukast
4.5710 mg (Pil)Montelukast
MDI, metered dose inhaler; DPI, dry-powder inhaler.
Original table is quoted from reference 4, and modified.
Table 2 Commonly used formulations of drugs used in asthma and COPD in Japan
PHARMACOLOGICAL TREATMENT FOR
STABLE COPD
Bronchodilators but not inhaled glucocorticosteroids
are the therapeutic mainstay for COPD patients.4
They include anticholinergics, beta agonists, and the-
ophylline. β2 agonists and anticholinergics are avail-
able in short-acting and long-acting inhaled formula-
tions. The scheme of the treatment for COPD is
shown in Figure 3. Table 2 shows commonly used
drugs used in COPD in Japan. In COPD, the order of
bronchodilators is inhaled anticholinergics, inhaled
β2-agonists and theophylline. Most bronchodilators
are administered by inhalation, orally, or intrave-
nously. A metered dose inhaler (MDI), dry powder
inhaler (DPI), or nebulizer can be used to deliver a
bronchodilator medication by inhalation. Moreover, it
is known that the long acting anticholinergics and
long acting β2-agonists work well in COPD.4,5 Combi-
nation therapy using inhaled glucocorticosteroids
plus long-acting β2 agonists significantly improves
some outcomes compared to placebo, long-acting β2
agonists alone, or inhaled glucocorticosteroids
alone.6
PHARMACOLOGICAL TREATMENT FOR
EXACERBATIONS OF COPD
GOLD defines an exacerbation of COPD as an acute
increase in symptoms beyond normal day-to-day vari-
ation.4 An exacerbation of COPD includes one or
Pharmacotherapy in Asthma and COPD
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Fig. 3 The scheme of the treatment for COPD. Quoted from reference 4.
I: Mild IV: Very SevereIII: SevereII: Moderate
● FEV1/FVC < 0.70
● FEV1 >_ 80% predicted
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
● FEV1/FVC < 0.70
● 50% <_ FEV1 < 80% 
ޓpredicted
Add regular treatment with one or more long-acting bronchodilators
(when needed); Add rehabilitation
● FEV1/FVC < 0.70
● 30% <_ FEV1 < 50% 
　predicted
Add inhaled glucocorticosteroids if
repeated exacerbations
● FEV1/FVC < 0.70
● FEV1 < 30% predicted
　or FEV1 < 50%
　predicted plus chronic
　respiratory failure
Add long term oxygen if
chronic respiratory
failure.
Consider surgical
treatments
more of the following symptoms: dyspnea increases,
cough increases in frequency and severity, and spu-
tum production increases in volume andor changes
character. The major components of managing an
acute exacerbation of COPD include inhaled short-
acting bronchodilators (beta adrenergic agonists and
anticholinergic agents), glucocorticosteroids, and an-
tibiotics.
BRONCHODILATORS
Increase dose andor frequency of existing short-
acting bronchodilator therapy, preferably inhaled
SABA such as salbutamol and procaterol in Japan. If
not already used, add anticholinergic agents until
symptoms improve. For example, inhaled short-
acting anticholinergic agents (e.g. ipratropium bro-
mide) can be used with SABAs to treat acute exacer-
bations of COPD.
GLUCOCORTICOSTEROIDS
Previous studies have shown that systemic glucocor-
ticoid therapy improves lung function and treatment
success, while reducing the length of hospital stay.7,8
The optimal dose of systemic glucocorticosteroids for
treating a COPD exacerbation is still unknown. If
baseline FEV1 <50% predicted, prednisone (30 to 40
mg orally, once daily) should be given for 7 to 10
days to the bronchodilator regimen.4 Methylpredni-
solone (60 to 125 mg, 2 to 4 times daily) are also used
intravenously. It is of note that high doses of systemic
glucocorticosteroids may increase the risk of side ef-
fects. Lower doses (e.g. 30 to 40 mg of prednisone)
may be equally effective and safe.4
ANTIBIOTICS
Antibiotics should be given to patients. Bacterial in-
fections appear to trigger one-third to one-half of
COPD exacerbations. Haemophilus influenzae,
Moraxella catarrhalis, and Streptococcus pneumoniae
are the bacteria most frequently isolated broncho-
scopically from patients having an exacerbation of
COPD. 9-11 Therefore, antibiotics including
amoxicillin-clavulanate, azithromycin, cefpodoxime,
cefprozil, cefuroxime, loracarbef, and the fluoroqui-
nolones are commonly used against H. influenzae, M.
catarrhalis, and S. pneumoniae for outpatients. For
hospitalized patients with risk factors for Pseudo-
monas, antibiotic choices include levofloxacin, ce-
fepime, ceftazidime, and piperacillin-tazobactam. Hos-
pitalized patients without risk factors for Pseudo-
monas can be treated with a respiratory fluoroqui-
nolone (levofloxacin, moxifloxacin) or a third-
generation cephalosporin (ceftriaxone or cefo-
taxime).12
Hoshino T et al.
346 Allergology International Vol 58, No3, 2009 www.jsaweb.jp
REFERENCES
1. Global Initiative for Asthma (GINA). Global Strategy for
Asthma Management and Preventation. Revised 2008.
Available at: http:www.ginasthma.com.
2. Haahtela T, Jarvinen M, Kava T et al. Comparison of a
beta 2-agonist, terbutaline, with an inhaled corticosteroid,
budesonide, in newly detected asthma. N Engl J Med
1991;325:388-92.
3. Emerman CL, Cydulka RK. A randomized comparison of
100-mg vs 500-mg dose of methylprednisolone in the
treatment of acute asthma. Chest 1995;107:1559-63.
4. Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Global Strategy for the Diagnosis, Management,
and Prevention of Chronic Obstructive Pulmonary Dis-
ease, NHLBIWHO Workshop Report. Revised 2006.
Available at: http:www.Goldcopd.Com. Accessed No-
vember 25, 2006.
5. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotro-
pium in chronic obstructive pulmonary disease. N Engl J
Med 2008;359:1543-54.
6. Calverley PM, Anderson JA, Celli B et al. Salmeterol and
fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med 2007;356:775-89.
7. Niewoehner DE, Erbland ML, Deupree RH et al. Effect of
systemic glucocorticoids on exacerbations of chronic ob-
structive pulmonary disease. Department of veterans af-
fairs cooperative study group. N Engl J Med 1999;340:
1941-7.
8. Quon BS, Gan WQ, Sin DD. Contemporary management
of acute exacerbations of COPD: A systematic review and
metaanalysis. Chest 2008;133:756-66.
9. Bartlett JG. Diagnostic accuracy of transtracheal aspira-
tion bacteriologic studies. Am Rev Respir Dis 1977;115:
777-82.
10. Soler N, Torres A, Ewig S et al. Bronchial microbial pat-
terns in severe exacerbations of chronic obstructive pul-
monary disease (COPD) requiring mechanical ventila-
tion. Am J Respir Crit Care Med 1998;157:1498-505.
11. Bandi V, Apicella MA, Mason E et al. Nontypeable hae-
mophilus influenzae in the lower respiratory tract of pa-
tients with chronic bronchitis. Am J Respir Crit Care Med
2001;164:2114-9.
12. Stoller JK. Clinical practice. Acute exacerbations of
chronic obstructive pulmonary disease. N Engl J Med
2002;346:988-94.
